不同公平关切视角下药品供应链定价及均衡策略研究

【作者】 李伟；

【导师】 温艳；

【作者基本信息】 青岛大学 ， 工业工程（专业学位）， 2019， 硕士

【摘要】 随着中国经济的快速发展,制药业发生了翻天覆地的变化。药品是一种关乎人类生命安全的重要商品,我国政府长久以来对药品价格实行的是政府定价,各种原因造成药品价格虚高,而随着新医改政策的全面实施,政府取消部分药品政府定价的决定,标志着药品正式进入市场化竞争环境。实现药品价格市场化,建立合理公平的价格秩序,不仅在于规范药品市场的竞争机制,更是可以改善药品价格虚高、老百姓看病贵的现实问题。药品供应链中的企业在实际运营过程中,不仅关注自身利益最大化,往往还会表现出因对方利润或者贡献导致的公平效用关注,本文正是从不同公平关切视角下对药品供应链的运营策略进行均衡分析,具有一定的理论价值和现实意义。通过文献综述,分析中国药品供应链的研究现状,对医保药品建立基本药品供应链博弈模型,将不同关切行为(绝对公平和相对公平)运用到药品供应链中,研究一个药品生产企业(领导者)和一个药品经销商(跟随者)构成的两级供应链系统的定价和均衡策略;然后针对非医保药品进行分析,也将不同关切行为(绝对公平和相对公平)运用到药品供应链中,研究一个药品生产企业(领导者)和两个药品经销商(跟随者)构成的竞争性两级供应链系统的均衡策略。研究表明:两种公平模型下药品经销商公平关切行为均不同程度的影响药品供应链成员的决策行为及系统绩效,公平关切行为是药品供应链中生产企业和经销商重新分配利润的一种手段;药品经销商的竞争强度也不同程度的影响药品供应链成员的定价决策。研究结论解释了政府对医保药品实行最高限价的原因,合理安排限价,防止医保药品价格过高,在取消限价后,政府应该确定合理的医药支付比例,从而发挥其对于药品市场价格的引导作用。更多还原

【Abstract】 With the rapid development of China’s economy,the pharmaceutical industry has undergone earth-shaking changes.Drugs are an important commodity related to the safety of human life.The government has long imposed government pricing on drug prices.The prices of drugs have been artificially high for various reasons.With the full implementation of the new medical reform policy,the government has cancelled the pricing of some drugs.The decision marks the official entry of the drug into a market-oriented competitive environment.To achieve marketization of drug prices and establish a reasonable and fair price order is not only to regulate the competition mechanism of the drug market,but also to improve the real problem of high drug prices and expensive medical treatment for the general public.In the actual operation process,enterprises in the pharmaceutical supply chain not only pay attention to maximizing their own interests,but also often show the fair utility concerns caused by the other party’s profits or contributions.This article is the operation of the pharmaceutical supply chain from different perspectives of fairness.The strategy of equilibrium analysis has certain theoretical and practical significance.Through literature review,analyze the research status of China’s pharmaceutical supply chain,establish a basic drug supply chain game model for medical insurance drugs,apply different concerns(absolute fairness and relative fairness)to the pharmaceutical supply chain,and study a pharmaceutical manufacturing enterprise(leader)And a drug dealer(follower)constitutes a two-tier supply chain system pricing and balancing strategy;then analyzes non-medical drugs,and applies different concerns(absolute fairness and relative fairness)to the drug supply chain,Study a balanced strategy for a competitive two-tier supply chain system consisting of a pharmaceutical manufacturing company(leader)and two drug distributors(followers).The research shows that the fairness behaviors of drug dealers under different fairness models affect the decision-making behavior and system performance of drug supply chain members to varying degrees.The fair concern behavior is a means for manufacturers and distributors to redistribute profits in the drug supply chain.The competitive intensity of drug dealers also affects the pricing decisions of members of the pharmaceutical supply chain to varying degrees.The conclusion of the study explains the reasons for the government to impose the maximum price limit for medical insurance drugs,reasonably arrange the price limit,and prevent the price of medical insurance drugs from being too high.After the price limit is cancelled,the government should determine the reasonable proportion of medical payment,so as to exert its price for the drug market.Guiding role.更多还原